Ouabain Octahydrate |
| Catalog No.GC10579 |
Ouabain Octahydrate is a Na+/K+-ATPase inhibitor that can be used to study congestive heart failure.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 11018-89-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ouabain Octahydrate is a Na+/K+-ATPase inhibitor that can be used to study congestive heart failure[1]. Ouabain Octahydrate can be used to induce cardiac dysfunction or hypertension models in animal models[2]. Ouabain Octahydrate can exert anti-cancer activity by downregulating intracellular signal transducer and activator of transcription 3 (STAT3)[3].
In vitro, Ouabain Octahydrate (3nM) treatment of autosomal dominant polycystic kidney disease (ADPKD) cells for 24h reduced the expression of epithelial cell marker E-cadherin in ADPKD cells, and increased the expression of mesenchymal cell markers N-cadherin, α-smooth muscle actin (αSMA), type I collagen, and tight junction proteins occludin and claudin-1[4]. Ouabain Octahydrate (25, 50, 100nM) treated Burkitt lymphoma Raji cells for 48h inhibited cell proliferation in a dose-dependent manner, significantly reduced cell viability, and induced cell autophagy[5].
In vivo, Ouabain Octahydrate (3mg/kg) was intraperitoneally injected into LPS-pretreated WT, IL-1β−/−, NLRP3−/−, Casp1−/− mice, which significantly reduced left ventricular systolic function in WT mice, increased plasma CPK levels and cardiac IL-1β protein levels, induced macrophage infiltration and myocardial damage, but these effects were significantly attenuated in IL-1β⁻/⁻, NLRP3⁻/⁻, and Casp1⁻/⁻ mice[6].
References:
[1] Harich O O, Gavriliuc O I, Ordodi V L, et al. In Vitro Study of the Multimodal Effect of Na+/K+ ATPase Blocker Ouabain on the Tumor Microenvironment and Malignant Cells[J]. Biomedicines, 2023, 11(8): 2205.
[2] Ferrari P, Ferrandi M, Valentini G, et al. Targeting Ouabain-and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach[J]. Medical Hypotheses, 2007, 68(6): 1307-1314.
[3] Du J, Jiang L, Chen F, et al. Cardiac glycoside ouabain exerts anticancer activity via downregulation of STAT3[J]. Frontiers in oncology, 2021, 11: 684316.
[4] Venugopal J, McDermott J, Sanchez G, et al. Ouabain promotes partial epithelial to mesenchymal transition (EMT) changes in human autosomal dominant polycystic kidney disease (ADPKD) cells[J]. Experimental cell research, 2017, 355(2): 142-152.
[5] Meng L, Wen Y, Zhou M, et al. Ouabain induces apoptosis and autophagy in Burkitt’s lymphoma Raji cells[J]. Biomedicine & Pharmacotherapy, 2016, 84: 1841-1848.
[6] Kobayashi M, Usui-Kawanishi F, Karasawa T, et al. The cardiac glycoside ouabain activates NLRP3 inflammasomes and promotes cardiac inflammation and dysfunction[J]. PloS one, 2017, 12(5): e0176676.
| Cell experiment [1]: | |
Cell lines | Autosomal dominant polycystic kidney disease (ADPKD) cells、normal human kidney (NHK) cells |
Preparation Method | Cultured ADPKD and NHK cells were treated without and with 3nM Ouabain Octahydrate for 24h. Cells were lysed and proteins of interest were identified by immunoblot. |
Reaction Conditions | 3nM; 24h |
Applications | ADPKD cells respond to Ouabain Octahydrate with a decrease in expression of the epithelial marker E-cadherin and increase in the expression of the mesenchymal markers N-cadherin, α smooth muscle actin (αSMA) and collagen-I, and the tight junction protein occludin and claudin-1. Other adhesion molecules, such as ZO-1, β-catenin and vinculin were not significantly modified by Ouabain Octahydrate.These effects of Ouabain Octahydrate were not observed in normal human kidney (NHK) cells. |
| Animal experiment [2]: | |
Animal models | WT, IL-1β−/−, NLRP3−/−, Casp1−/− mice |
Preparation Method | Mice were "primed" by intraperitoneal injection of low-dose lipopolysaccharide (LPS, 2mg/kg). 12h after LPS injection, Ouabain Octahydrate (3mg/kg) was injected intraperitoneally; the control group was injected with an equal volume of normal saline. Left ventricular systolic function (%FS, EF), left ventricular end-diastolic diameter (LVEDD) and end-systolic diameter (LVESD) were evaluated by echocardiography. Plasma creatine phosphokinase (CPK, a marker of myocardial injury) and cardiac tissue IL-1β levels were detected by ELISA. |
Dosage form | 3mg/kg; i.p. |
Applications | Ouabain Octahydrate (3mg/kg) significantly reduced left ventricular systolic function (decreased %FS and EF, increased LVESD), increased plasma CPK levels and cardiac IL-1β protein levels only in LPS-pretreated WT mice. These effects were significantly attenuated in IL-1β⁻/⁻, NLRP3⁻/⁻, or Casp1⁻/⁻ mice. |
References: | |
| Cas No. | 11018-89-6 | SDF | |
| Chemical Name | 3-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one | ||
| Canonical SMILES | CC1C(C(C(C(O1)OC2CC(C3(C4C(CCC3(C2)O)C5(CCC(C5(CC4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O | ||
| Formula | C29H60O20 | M.Wt | 728.77 |
| Solubility | ≥ 19.5mg/mL in H20 with ultrasonic and warming | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3722 mL | 6.8609 mL | 13.7218 mL |
| 5 mM | 0.2744 mL | 1.3722 mL | 2.7444 mL |
| 10 mM | 0.1372 mL | 0.6861 mL | 1.3722 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *